CARM · As filed with the SEC

Carisma Therapeutics balance sheet, by fiscal year

The statement as Carisma Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Consolidated Balance Sheets · USD thousands

USD thousands	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017
Assets
Current assets:
Cash and cash equivalents	17,909	77,605	112,553	162,636	52,389	48,121	50,422	14,680
Marketable securities	—	0	54,366	—	—	—	—	—
Restricted cash	—	—	21,000	0	3,000	—	—	—
Accounts receivables	—	—	0	21,011	—	—	—	—
Other receivables	—	—	825	3,482	—	—	—	—
Prepaid expenses and other assets	5,916	2,866	400	18,476	7,478	6,326	1,334	301
Total current assets	23,825	80,471	189,144	205,605	62,867	54,447	51,756	14,981
Restricted cash	—	—	30	20	20	20	20	10
Property and equipment, net	—	—	0	43	123	238	321	522
Intangible assets	—	—	0	14,700	46,400	46,400	46,400	46,400
Goodwill	—	—	0	13,064	13,064	13,064	13,064	13,064
Long term prepaid expenses	—	—	0	7,192	—	—	—	—
Other assets	—	—	0	123	349	196	0	120
Total non-current assets	—	—	30	35,142	—	—	—	—
Property and equipment, net	4,385	6,764	—	—	—	—	—	—
Right of use assets – operating leases	2,040	2,173	—	—	—	—	—	—
Deferred financing costs	—	146	—	—	—	—	—	—
Deferred financing costs	208	—	—	—	—	—	—	—
Total assets	30,458	89,554	189,174	240,747	122,823	114,365	111,561	75,097
Liabilities and Stockholders' (Deficit) Equity
Current liabilities:
Accounts payable	2,081	3,933	1,233	2,853	3,102	1,902	1,367	907
Accrued expenses	7,448	7,662	29,636	8,255	3,973	6,169	4,746	3,813
Deferred revenue	—	—	—	0	1,500	—	—	—
Contingent consideration	—	—	—	0	—	—	—	—
Deferred revenue	3,729	1,413	—	—	—	—	—	0
Due to related party	—	—	—	—	—	—	—	0
Operating lease liabilities	832	1,391	—	—	—	—	—	—
Finance lease liabilities	905	544	—	—	—	—	—	—
Other current liabilities	1,060	965	115	460	489	446	—	—
Total current liabilities	16,055	15,908	30,984	11,568	18,049	8,517	6,113	4,720
Contingent consideration	—	—	0	52,000	99,855	120,020	48,400	39,600
Deferred tax liability	—	—	0	3,969	12,528	12,528	12,528	12,528
Deferred revenue	—	—	0	1,500	1,500	—	—	—
Total non-current liabilities	—	—	0	57,469	—	—	—	—
Deferred revenue	41,250	45,000	—	—	—	—	—	—
Convertible promissory note	—	0	—	—	—	—	—	—
Derivative liability	—	0	—	—	—	—	—	—
Operating lease liabilities	724	860	—	—	—	—	—	—
Finance lease liabilities	20	328	—	—	—	—	—	—
Other long-term liabilities	318	926	—	0	118	0	313	215
Warrant liability	—	—	—	—	—	—	—	0
Total liabilities	58,367	63,022	30,984	69,037	132,050	141,065	—	—
Convertible preferred stock	—	0	—	—	—	—	—	—
Stockholders’ (deficit) equity:
Preferred stock $0.001 par value, 5,000,000 shares authorized, none issued or outstanding	0	0	0	0	0	0	0	0
Common stock $0.001 par value, 350,000,000 shares authorized, 41,750,109 and 40,609,915 shares issued and outstanding at December 31, 2024 and 2023, respectively	41	40	202	199	140	107	77	35
Additional paid-in capital	277,629	271,594	494,675	487,768	306,554	266,717	230,154	170,330
Accumulated other comprehensive loss	—	0	(546)	—	—	—	—	—
Accumulated deficit	(305,579)	(245,102)	(336,141)	(316,257)	(315,921)	(293,524)	(186,024)	(152,331)
Total Carisma Therapeutics Inc. stockholders’ equity (deficit)	—	26,532	158,190	171,710	(9,227)	(26,700)	44,207	18,034
Noncontrolling interests	—	0	—	—	—	—	—	—
Total stockholders’ (deficit) equity	(27,909)	26,532	—	—	—	—	—	—
Total liabilities and stockholders’ (deficit) equity	30,458	89,554	189,174	240,747	122,823	114,365	111,561	75,097

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.